Roth Capital adjusted the firm’s price target on Cellectar Biosciences (CLRB) to $18 from $3 and keeps a Buy rating on the shares post the Q2 report. The new price target largely reflects the company’s reverse split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB: